CECCON, CARLOTTA

CECCON, CARLOTTA  

Università di Padova  

Mostra records
Risultati 1 - 7 di 7 (tempo di esecuzione: 0.016 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint 2022 Cappello F.Angerilli V.Munari G.Ceccon C.Sabbadin M.Fassan M. + JOURNAL OF PERSONALIZED MEDICINE - -
IMMUNOREACT 8: Immune markers of local tumor spread in patients undergoing transanal excision for clinically N0 rectal cancer 2025 Scarpa, MelaniaKotsafti, AndromachiFassan, MatteoGuzzardo, VincenzaSalmaso, RobertaCarlotta, CecconDei Tos, Angelo PaoloAngriman, ImerioSpolverato, GayaPucciarelli, SalvatorePorzionato, AndreaAgostini, MarcoTussardi, GaiaDi Camillo, BarbaraBardini, RomeoCastagliuolo, IgnazioScarpa, Marco + SURGERY - -
IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions 2024 Scarpa, MelaniaSalmaso, RobertaKotsafti, AndromachiGregori, DarioSpolverato, GayaAngriman, ImerioGuzzardo, VincenzaCarlotta, CecconDei Tos, Angelo PaoloPorzionato, AndreaAgostini, MarcoTussardi, GaiaDi Camillo, BarbaraBardini, RomeoCastagliuolo, IgnazioPucciarelli, SalvatoreFassan, MatteoScarpa, Marco + SCIENTIFIC REPORTS - -
Liquid biopsy in gastric cancer: A snapshot of the current state of the art 2025 Gasparello, JessicaCeccon, CarlottaFassan, Matteo + THE JOURNAL OF LIQUID BIOPSY - -
Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches 2022 Ceccon, CarlottaAngerilli, ValentinaRasola, CosimoProcaccio, LetiziaSabbadin, MariannaLonardi, SaraFassan, Matteo + FRONTIERS IN ONCOLOGY - -
MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma 2025 Ceccon, CarlottaBorga, ChiaraGasparello, JessicaSchiavi, FrancescaScarpa, MarcoUrso, Emanuele Damiano LucaDei Tos, Angelo PaoloFassan, Matteo + PATHOLOGY RESEARCH AND PRACTICE - -
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial 2024 Fassan M.Ceccon C. + THE LANCET ONCOLOGY - -